In a randomized , multicenter , 80-week trial , liver transplant recipients ( > 6 months and 10 years post-transplant ) with recurrent HCV infection received cyclosporine ( n = 50 ) or tacrolimus ( n = 42 ) with a 48-week course of pegylated interferon ( peg-IFN2a ) and ribavirin .